Myoview .23 mg/1 (Tetrofosmin INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) .23 mg/1

Myoview .23 mg/1 is a lyophilized powder for solution, used in medical imaging. This tetrofosmin-based injection aids in diagnostic procedures, offering clarity for healthcare professionals.

Strength

.23 mg/1

Pack Size

5 VIAL in 1 KIT (17156-024-05) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL

Manufacturer / TM Owner

Medi-Physics Inc. dba GE Healthcare

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Myoview .23 mg/1 is primarily used in myocardial perfusion imaging to assess blood flow to the heart. This diagnostic tool helps in evaluating heart function and identifying areas with reduced blood flow. Healthcare providers may use it to support the diagnosis and management of certain cardiac conditions.

Side Effects

Myoview .23 mg/1 is designed to be administered intravenously and works by distributing within the body to highlight areas of interest during imaging. The effects are typically monitored through specialized imaging equipment, providing visual data for diagnostic purposes.

Precautions & Warnings

As with any medical product, Myoview .23 mg/1 should be handled with care. It is important to follow proper procedures for preparation and administration to ensure safety. Always consult healthcare guidelines and professional advice for specific handling instructions.

Avoid Interactions

Myoview .23 mg/1 may interact with certain medications or substances. It is advisable to inform healthcare providers about all current medications to avoid potential interactions. Always follow professional advice regarding the use of this product.

Frequently Asked Questions

Myoview .23 mg/1 is used in myocardial perfusion imaging to assess heart blood flow and function.

Myoview .23 mg/1 is administered intravenously after being reconstituted from its lyophilized powder form.

The effects of Myoview .23 mg/1 are typically monitored through imaging equipment to provide diagnostic data.

Yes, proper handling and administration procedures should be followed to ensure safety.

Potential interactions may occur, so it is important to inform healthcare providers about all current medications.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.